Immune checkpoint inhibitors, such as anti-PD-1 (e.g., pembrolizumab) and anti-CTLA-4 (e.g., ipilimumab) antibodies, have revolutionized cancer treatment by reactivating antitumor immunity and are now being explored in sepsis to reverse immune paralysis and restore immune function. This evidence concerns the gene PDCD1 and cancer.